8 June 2021 - Glaukos Corporation today announced that the TGA has granted regulatory approval for the Preserflo MicroShunt intended for the reduction of intra-ocular pressure in eyes of patients with primary open-angle glaucoma where intra-ocular pressure remains uncontrollable while on maximum tolerated medical therapy and/or where glaucoma progression warrants surgery.

The Preserflo MicroShunt is an ab-externo, drainage system that helps drain eye fluid and reduces intra-ocular pressure in patients with primary open-angle glaucoma whose intra-ocular pressure is not controlled when using maximum tolerated glaucoma medications or where glaucoma progression warrants surgery.

Read Glaukos Corporation press release